NDA 014134 · Baxter Hlthcare Corp
Protopam Chloride
Pralidoxime Chloride · Injection
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 15, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Mar 11, 1964
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 1 recruiting
FAERS reports
26
15 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2026.
INDICATIONS AND USAGE PROTOPAM Chloride is indicated as an antidote: (1) in the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and (2) in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 11, 1964 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- PROTOPAM CHLORIDE · PRALIDOXIME CHLORIDE 1GM/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pralidoxime Chloride" as an intervention, any sponsor and status, largest first.
- Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.Pivotal-lookingCompleted
Giriraj HospitalAcademic, hospital or other
NCT00333944 · 200 participants · Start May 2000
Drug: Pralidoxime(drug) · For: Acute Organophosphorus Pesticide Poisoning
Sites: Baramati. Pune District., India
- Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?Pivotal-lookingCompleted
Sheri Kashmir Institute of Medical SciencesAcademic, hospital or other
NCT02040350 · 100 participants · Start Apr 2012 · Primary completion Aug 2013
Drug: Pralidoxime · For: Deaths
Sites: Srinagar, India
Sir Salimullah Medical College Mitford HospitalGovernment (non-federal)
NCT06111352 · 96 participants · Start Jun 1, 2022 · Primary completion Sep 30, 2023
Drug: Pralidoxime; Atropine · For: Organophosphorus Poisoning
Sites: Dhaka, Bangladesh
- Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP PoisoningPivotal-lookingCompleted
Sylhet M.A.G.Osmani Medical CollegeAcademic, hospital or other
NCT02160548 · 75 participants · Start Apr 2015 · Primary completion Dec 2015
Drug: Standard care; Standard care+ 2.5 mg Salbutamol and 1 more · For: Organophosphate Poisoning
Sites: Sylhet, Bangladesh
Muhammad Aamir LatifAcademic, hospital or other
NCT07777835 · 38 participants (planned) · Start May 10, 2026 · Primary completion Oct 10, 2026
Drug: Atropine plus pralidoxime; Atropine and pralidoxime with adjunctive MgSO4 · For: Organophosphate Poisoning
Sites: Multan, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- accidental exposure6
- expired drug administered5
- injection site injury4
- drug ineffective3
- accidental exposure to product2
- expired product administered2
- extrapyramidal disorder2
- injection site pain2
- mental disorder due to a general medical condition2
- peripheral swelling2
- agitation1
- agranulocytosis1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Does pralidoxime affect outcome of management in acute organophosphorus poisoning?
de Silva HJ, Wijewickrema R, Senanayake N · Lancet 1992 · Clinical Trial, Comparative Study
- Oximes for acute organophosphate pesticide poisoning.
Buckley NA, Eddleston M, Li Y, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
- [Transcutaneous Electrical Stimulation Undergoing Emergency Treatment of Zusanli (ST 36) Is Beneficial to Rescued Organophosphorus Pesticide Poisoning Patients].
Gao H, Zhao ML, Zhou AM, et al. · Zhen Ci Yan Jiu 2015 · English Abstract, Randomized Controlled Trial
- [Clinical trial on standard treatment of acute organophosphorus poisoning].
Yan YJ, Li XJ, Ning GY, et al. · Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2010 · Clinical Trial, English Abstract
- Pralidoxime in acute organophosphorus insecticide poisoning--a randomised controlled trial.
Eddleston M, Eyer P, Worek F, et al. · PLoS Med 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Improvement of motor function in multiple sclerosis by use of protopam chloride.
Cook AW, Nidzgorski F, Oygar A · Acupunct Electrother Res 1992 · Clinical Trial, Controlled Clinical Trial
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.